参考文献/References:
[1].Rao SV,Ohman EM. Anticoagulant therapy for percutaneous coronary intervention[J]. Circ Cardiovasc Interv,2010,3(1):80-88.
[2].Gopalakrishnan M,Lotfi AS. Stent thrombosis[J]. Semin Thromb Hemost,2018,44(1):46-51.
[3].Burzotta F,Parma A,Pristipino C,et al. Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents:the OPTIMIST study[J]. Eur Heart J,2008,29(24):3011-3021.
[4].Hirsh J,Anand SS,Halperin JL,et al. Mechanism of action and pharmacology of unfractionated heparin[J]. Arterioscler Thromb Vasc Biol,2001,21(7):1094-1096.
[5].Ibánez B,James S,Agewall S,et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J]. Rev Esp Cardiol(Engl Ed),2017,70(12):1082.
[6].Dillinger JG,Ducrocq G,Elbez Y,et al. Activated clotting time to guide heparin dosing in non-ST-segment-elevation acute coronary syndrome patients undergoing percutaneous coronary intervention and treated withⅡb/Ⅲa inhibitors:impact on ischemic and bleeding outcomes:insights from the TAO trial[J]. Circ Cardiovasc Interv,2018,11(6):e006084.
[7].Weitz JI. Low-molecular-weight heparins[J]. N Engl J Med,1997,337(10):688-698.
[8].Arsenault KA,Hirsh J,Whitlock RP,et al. Direct thrombin inhibitors in cardiovascular disease[J]. Nat Rev Cardiol,2012,9(7):402-414.
[9].Keam SJ,Goa KL. Fondaparinux sodium[J]. Drugs,2002,62(11):1673-1685.
[10].Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators,Yusuf S,Mehta SR,et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes[J]. N Engl J Med ,2006,354 (14):1464-1476.
[11].Yusuf S,Mehta SR,Chrolavicius S,et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction:the OASIS-6 randomized trial[J]. JAMA,2006,295(13):1519-1530.
[12].Cohen M,Adams PC,Parry G,et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group[J]. Circulation,1994,89(1):81-88.
[13].Gurfinkel EP,Manos EJ,Mejaíl RI,et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia[J]. J Am Coll Cardiol,1995,26(2):313-318.
[14].Chen JY,He PC,Liu YH,et al. Association of parenteral anticoagulation therapy with outcomes in Chinese patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome[J]. JAMA Intern Med,2019,179(2):186-194.
[15].Liu YH,Fan HL,Zeng LH,et al. Association of parenteral anticoagulation therapy with outcomes in non-ST-segment elevation acute coronary syndrome patients without invasive therapy:findings from the improving Care for Cardiovascular Disease in China (CCC) project[J]. Clin Pharmacol Ther,2021,110(4):1119-1126.
[16].Li YJ,Rha SW,Chen KY,et al. Low molecular weight heparin versus unfractionated heparin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention with drug-eluting stents[J]. J Cardiol,2012,59(1):22-29.
[17].Mallidi JR,Robinson P,Visintainer PF,et al. Comparison of antithrombotic agents during urgent percutaneous coronary intervention following thrombolytic therapy:a retrospective cohort study[J]. Catheter Cardiovasc Interv,2017,90 (6):898-904.
[18].Valgimigli M,Frigoli E,Leonardi S,et al. Bivalirudin or unfractionated heparin in acute coronary syndromes[J]. N Engl J Med,2015,373(11):997-1009.
[19].O’Gara PT,Kushner FG,Ascheim DD,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol,2013,61(4):e78-e140.
[20].Collet JP,Thiele H,Barbato E,et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation[J]. Eur Heart J,2021,42(14):1289-1367.
[21].中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 急性ST段抬高型心肌梗死诊断和治疗指南[J]. 中华心血管病杂志,2015,43(5):380-393.
[22].中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 非ST段抬高型急性冠状动脉综合征诊断和治疗指南(2016)[J]. 中华心血管病杂志,2017,45(5):359-376.
[23].韩雅玲,傅向华. 经皮冠状动脉介入治疗围手术期非口服抗凝药物临床应用中国专家共识[J]. 中华心血管病杂志,2018,46(6):428-437.
[24].Madhavan MV,Généreux P,Kirtane AJ,et al. Is routine post-procedural anticoagulation warranted after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction? Insights from the HORIZONS-AMI trial[J]. Eur Heart J Acute Cardiovasc Care,2017,6(7):650-658.
[25].Ducrocq G,Steg PG,Van’t Hof A,et al. Utility of post-procedural anticoagulation after primary PCI for STEMI:insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials[J]. Eur Heart J Acute Cardiovasc Care,2017,6(7):659-665.
[26].Gargiulo G,Carrara G,Frigoli E,et al. Post-procedural bivalirudin infusion at?full or low regimen in patients with?acute coronary syndrome[J]. J Am Coll Cardiol,2019,73(7): 758-774.
[27].Yan Y,Gong W,Ma C,et al. Postprocedure anticoagulation in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. JACC Cardiovasc Interv,2022,15(3):251-263.
[28].Gragnano F,Calabrò P. Anticoagulation after primary PCI:the land of promises and uncertainty[J]. JACC Cardiovasc Interv,2022,15(3):264-267.
[29].Yan Y,Wang X,Guo J,et al. Rationale and design of the RIGHT trial:a multicenter,randomized,double-blind,placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction[J]. Am Heart J,2020,227:19-30.
相似文献/References:
[1]李润土,何泉.光学相干断层成像在急性冠脉综合征介入治疗中的应用[J].心血管病学进展,2019,(6):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
LI Runtu,HE Quan.Application of Optical Coherent Tomography in Interventional Treatment of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(1):856.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.005]
[2]郑晓雪 季福绥.急性冠脉综合征患者发生急性肾损伤的临床进展[J].心血管病学进展,2019,(5):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
ZHENG Xiaoxue,JI Fusui.Acute Kidney Injury in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(1):713.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.013]
[3]周小琳 何泉.替格瑞洛在急性冠脉综合征合并慢性肾脏病患者中的应用研究进展[J].心血管病学进展,2019,(5):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
ZHOU Xiaolin,HE Quan.Ticagrelor in Acute Coronary Syndrome with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2019,(1):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
[4]吕俊兴 许海燕.急性冠脉综合征危险评分的研究进展[J].心血管病学进展,2019,(9):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
LU Junxing,XU Haiyan.Risk Scores of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(1):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
[5]吕颖 胡思宁 于波 贾海波.斑块侵蚀发病机制的最新研究进展[J].心血管病学进展,2020,(1):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
LU Ying,HU Sining,YU Bo,et al.Pathogenic Mechanisms of Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(1):74.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.020]
[6]段继坤,林志,杨帆,等.斑块侵蚀引起的急性冠脉综合征的研究新进展[J].心血管病学进展,2020,(3):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
DUAN Jikun,LIN Zhi,YANG Fan,et al.Acute Coronary Syndrome Caused by Plaque Erosion[J].Advances in Cardiovascular Diseases,2020,(1):281.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.016]
[7]韩培天 魏晓岩 杜彬彬 张津宁 王文州 郭艳娇 张克成 李春彦 李文慧.心肌缺血时间对STEMI患者急诊PCI术后早期左室舒张功能的影响及相关因素分析[J].心血管病学进展,2020,(6):660.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.024]
HAN Pei-tian,WEI Xiaoyan,DU Binbin,et al.Effect of Myocardial Ischemia Duration on Early Left Ventricular Diastolic Function in STEMI Patients After Emergency PCI and Analysis of Related Factors[J].Advances in Cardiovascular Diseases,2020,(1):660.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.024]
[8]陈凯磊 胡闻竹 苏冠华.P2Y12抑制剂与癌症风险的相关性研究进展[J].心血管病学进展,2020,(8):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
CHEN Kailei,HU Wenzhu,SU Guanhua.Advances in Studies on the Correlation between P2Y12 Inhibitors and Cancer Risk[J].Advances in Cardiovascular Diseases,2020,(1):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
[9]肖雨尘 赵仙先 马丽萍.急性冠脉综合征患者提前停服替格瑞洛现象的研究进展[J].心血管病学进展,2020,(11):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
Acute Coronary Syndrome.Premature Ticagrelor Discontinuation in Patients with[J].Advances in Cardiovascular Diseases,2020,(1):1120.[doi:10.16806/j.cnki.issn.1004-3934.2020.11.000]
[10]冯洁渊 .中性粒细胞/淋巴细胞比值和血小板/淋巴细胞比值与急性冠脉综合征的关系研究进展[J].心血管病学进展,2020,(12):1276.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.013]
FENG Jieyuan.The Relationship Between Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio and Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2020,(1):1276.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.013]
[11]王晓黎 宋莉 颜红兵.急性冠脉综合征患者经皮冠状动脉介入治疗术后对比剂肾病的防治进展[J].心血管病学进展,2023,(2):127.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.007]
WANG XiaoliSONG LiYAN Hongbing.Prevention of Contrast Induced Nephropathy after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2023,(1):127.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.007]